Education
About Us
Working with TipRanks
Follow Us
Applied Therapeutics (DE:2UV)
:2UV
2UV Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.41 - €9.49
Previous CloseN/A
Volume700.00
Average Volume (3M)80.00
Market Cap
€57.62M
Enterprise Value€1.13B
Total Cash (Recent Filing)$49.90M
Total Debt (Recent Filing)$777.00K
Price to Earnings (P/E)―
Beta-1.65
Next Earnings
Mar 14, 2025EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding116,356,476
10 Day Avg. Volume200
30 Day Avg. Volume80
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.96
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap19.61
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit117.22
Enterprise Value/Ebitda-12.26
Forecast
1Y Price Target
€1.38Price Target Upside212.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bulls Say, Bears Say
Bulls Say
Leadership ChangeAPLT has announced John H. Johnson, an industry veteran with more than 40 years of experience, will serve as Executive Chairman, and Les Funtleyder, who is currently the CFO and has served on APLT's board, will serve as interim CEO.
Product SupportGovorestat still has a lot of support from the galactosemia KOL community and patient advocates, highlighting the unmet need.
Bears Say
Regulatory ChallengesThe FDA's warning letter has significantly affected management’s reputation, likely impacting near-term investor sentiment.
---
2UV FAQ
What was Applied Therapeutics’s price range in the past 12 months?
Applied Therapeutics lowest stock price was €0.41 and its highest was €9.49 in the past 12 months.
What is Applied Therapeutics’s market cap?
Applied Therapeutics’s market cap is €57.62M.
When is Applied Therapeutics’s upcoming earnings report date?
Applied Therapeutics’s upcoming earnings report date is Mar 14, 2025 which is in 2 days.
How were Applied Therapeutics’s earnings last quarter?
Applied Therapeutics released its earnings results on Nov 07, 2024. The company reported -€0.443 earnings per share for the quarter, missing the consensus estimate of -€0.146 by -€0.297.
Is Applied Therapeutics overvalued?
According to Wall Street analysts Applied Therapeutics’s price is currently Undervalued.
Does Applied Therapeutics pay dividends?
Applied Therapeutics does not currently pay dividends.
What is Applied Therapeutics’s EPS estimate?
Applied Therapeutics’s EPS estimate is -0.17.
How many shares outstanding does Applied Therapeutics have?
Applied Therapeutics has 116,356,476 shares outstanding.
What happened to Applied Therapeutics’s price movement after its last earnings report?
Applied Therapeutics reported an EPS of -€0.443 in its last earnings report, missing expectations of -€0.146. Following the earnings report the stock price went down -2.93%.
Which hedge fund is a major shareholder of Applied Therapeutics?
Currently, no hedge funds are holding shares in DE:2UV
---
Applied Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€1.38 (212.58% Upside)
€1.38 (212.58% Upside)
Blogger Sentiment
Bullish
DE:2UV Sentiment 70%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $94.8K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-91.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
135.79%
Trailing 12-Months
Company Description
Applied Therapeutics
Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.
---
2UV Stock 12 Month Forecast
Average Price Target
€1.38
▲(212.58% Upside)
Technical Analysis
Xoma
―
RedHill Biopharma
―
Ocular Therapeutix
―
Protagonist Therapeutics
―
Annovis Bio
―
Best Analysts Covering 2UV
1 Year
1 Year Success Rate
11/32 ratings generated profit
1 Year Average Return
+55.88%
reiterated a buy rating 3 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 34.38% of your transactions generating a profit, with an average return of +55.88% per trade.
---